





DI-057

A. Rodríguez-Perez¹, M.I. Sierra-Torres¹, ER Alfaro-Lara², MD Toscano-Guzmán¹, M Galván-Banqueri², B.Santos-Ramos³ ¹UGC Farmacia. Hospital Universitario Virgen del Rocío. Seville. Spain

²Agencia de Evaluación de Tecnologías Sanitarias de Andalucía. Seville. Spain

³UGC Farmacia. Área de Gestión Sanitaria Sur. Seville. Spain



LESS-CHRON CRITERIA IS A NEW CREATION LIST OF TWENTY-SEVEN ITEMS TO GUIDE DEPRESCRIBING

Each item consist of:

OBJECTIVE

To analyze the utility of a new tool to guide deprescribing in patients with chronic pathologies.

Drug and its indication/ deprescribing condition/ health variable to monitor after deprescribing/period of follow up.

MATERIAL AND METHODS

A chart review was developed by a pharmacist in July 2015.

Consent was requested to the service of clinical documentation and statistic from the hospital.

Inclusion criteria for patients to analyze were: being eighty years old or older, having a summary discharge from the internal medicine unit between September 2014 - May 2015, suffering from a pathology of the ones considered as indications of the possible drugs to deprescribe, presenting active prescriptions of drugs in the sanitary card and be alive at the moment of the study.

the second secon

LESS-CHRON criteria were applied using information from the patient's chart. There were collected: age, sex and number of active drugs. There was analyzed: number of items of the tool possible to apply in the sample, drugs more frecuently considered options to deprescribe, as well as items applied for patients.



Patients with no item to apply: 8

Maximum numbers of items possible to

apply in a patient : 5



antihypertensives

benzodiazepines and zolpidem/zaleplon for insomnia

benzodiazepines for anxiety

alpha-adrenergic blockers for benign prostatic hypertrophy

LESS-CHRON criteria are a useful tool to guide deprescribing drugs in older and chronic patients. Drugs more frecuently deprescribed agree with the literature. It is necessary to validate this results in clinical trial

CONCLUSION

21st EAHP Congress – Vienna, Austria 16-18 March, 2016